Clinical trial
A Study in Participants With Moderate to Severe Psoriasis
NCT01107457
Study timeline
Study start (unknown)2010-04-01Date precision: month
Registry last updated2019-09-24
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Psoriasisunresolved
Interventions
IxekizumabBIOLOGICAL
PlaceboDRUG
Sponsors & collaborators
Eli Lilly and Companylead sponsor
Mapped research locations
New YorkNew York, United States1BostonMassachusetts, United States1PhiladelphiaPennsylvania, United States1DallasTexas, United States1St LouisMissouri, United States1MiamiFlorida, United States1San AntonioTexas, United States1NashvilleTennessee, United States1ClevelandOhio, United States1PortlandOregon, United States1Washington D.C.District of Columbia, United States1OmahaNebraska, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01107457 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.